Case Report: Successful Treatment of Kaposi’s Sarcoma With Anlotinib in an HIV-Negative Patient After the Treatment of Drug Reaction With Eosinophilia and Systemic Symptoms Accessory Tragus
暂无分享,去创建一个
Chao Ji | Z. Xiao | Renwei Luo | Min Lin | Peng Zhang | T. Gong
[1] Wei Sun,et al. Effectiveness and Safety of Anlotinib Monotherapy for Patients with Extensive-stage Small-Cell Lung Cancer Who Progressed to Chemotherapy: A Real-world Exploratory Study , 2022, Clinical Medicine Insights. Oncology.
[2] G. Bao,et al. Effectiveness and safety of pegylated liposomal doxorubicin versus epirubicin as neoadjuvant or adjuvant chemotherapy for breast cancer: a real-world study , 2021, BMC Cancer.
[3] Ben Ma,et al. The Efficacy and Safety of Anlotinib in Neoadjuvant Treatment of Locally Advanced Thyroid Cancer: A Single-arm Phase II Clinical Trial. , 2021, Thyroid : official journal of the American Thyroid Association.
[4] Shenglong Li. Anlotinib: A Novel Targeted Drug for Bone and Soft Tissue Sarcoma , 2021, Frontiers in Oncology.
[5] A. Perrone,et al. Electrochemotherapy in Kaposi sarcoma: A systematic review. , 2021, Molecular and clinical oncology.
[6] İ. Aral,et al. Palliative treatment of Kaposi sarcoma with radiotherapy: a single center experience , 2021, Radiation oncology journal.
[7] Y. Sun,et al. [Long term follow-up results of anlotinib in the treatment of advanced renal cell carcinoma]. , 2020, Zhonghua zhong liu za zhi [Chinese journal of oncology].
[8] T. Shiohara,et al. Drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS): An update in 2019. , 2019, Allergology international : official journal of the Japanese Society of Allergology.
[9] I. Zalaudek,et al. Diagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC). , 2019, European journal of cancer.
[10] S. Steinberg,et al. A Pilot Study of Liposomal Doxorubicin Combined with Bevacizumab followed by Bevacizumab Monotherapy in Patients with Advanced Kaposi Sarcoma , 2019, Clinical Cancer Research.
[11] Z. Duan,et al. Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma , 2019, International journal of cancer.
[12] M. Rudek,et al. Phase II trial of imatinib in AIDS-associated Kaposi's sarcoma: AIDS Malignancy Consortium Protocol 042. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] L. Pantanowitz,et al. Kaposi sarcoma. , 2013, Archives of pathology & laboratory medicine.
[14] K. Tkaczuk,et al. Update on taxane development: new analogs and new formulations , 2012, Drug design, development and therapy.
[15] E. Mohammadi,et al. Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.
[16] M. Lagunoff,et al. KSHV Induction of Angiogenic and Lymphangiogenic Phenotypes , 2012, Front. Microbio..
[17] A. Tourlaki,et al. Intralesional vincristine as first‐line therapy for nodular lesions in classic Kaposi sarcoma: a prospective study in 151 patients , 2009, The British journal of dermatology.
[18] Anthony Marmarou,et al. Diagnosis and management of idiopathic normal-pressure hydrocephalus: a prospective study in 151 patients. , 2005, Journal of neurosurgery.
[19] Kaposi,et al. Idiopathisches multiples Pigmentsarkom der Haut , 1872, Archiv für Dermatologie und Syphilis.
[20] D. Donnell,et al. Phase III Vehicle-Controlled, Multi-Centered Study of Topical Alitretinoin Gel 0.1% in Cutaneous AIDS-Related Kaposi’s Sarcoma , 2001, American journal of clinical dermatology.